BioCentury | Aug 1, 2016
Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
BC Week In Review | May 25, 2015
Clinical News

ChAd3-EBO-Z: Phase I started

Oxford University began a U.K. Phase I trial to evaluate intramuscular ChAd3-EBO-Z prime followed by intramuscular MVA EBOZ boost after 1 week vs. MVA EBOZ as a monotherapy in 38 volunteers. GlaxoSmithKline’s MVA EBOZ, a...
BC Week In Review | May 25, 2015
Clinical News

MVA EBOZ: Phase I started

Oxford University began a U.K. Phase I trial to evaluate intramuscular ChAd3-EBO-Z prime followed by intramuscular MVA EBOZ boost after 1 week vs. MVA EBOZ as a monotherapy in 38 volunteers. GlaxoSmithKline’s ChAd3-EBO-Z, a recombinant...
BC Week In Review | Dec 22, 2014
Clinical News

cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z...
BC Week In Review | Dec 22, 2014
Clinical News

MVA-BN Filo: Phase I started

Bavarian Nordic said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from GlaxoSmithKline plc (LSE:GSK;...
BC Week In Review | Oct 27, 2014
Clinical News

cAd3-EBO Z: Phase Ib started

The University of Maryland , the Center for Vaccine Development of Mali and the Malian Ministry of Health began an open-label, dose-escalation Phase Ib trial to evaluate 2 dose levels of intramuscular cAd3-EBO Z in 40...
Items per page:
1 - 6 of 6